Defendant

Roxane/Hikma

2 cases as defendant.

Cases
2
Active
2
0 closed
Filed
2020
Top venue
N.D. California
1 case

Company profile

Roxane/Hikma is the informal label used in this database for Roxane Laboratories, Inc., a U.S. specialty-generics manufacturer based at 1809 Wilson Road, Columbus, Ohio. The business traces to 1885, when it was founded as The Columbus Pharmaceutical Company (later Columbus Pharmacal, then Philips Roxane). Boehringer Ingelheim acquired it in 1978 and renamed it Roxane Laboratories. Hikma Pharmaceuticals PLC acquired Roxane in 2016 in a deal announced at about $2.65 billion (closed at roughly $2.1 billion); Roxane Laboratories, Inc. became Hikma Labs Inc. and Boehringer Ingelheim Roxane Inc. became West-Ward Columbus Inc. Hikma Pharmaceuticals PLC is a London-headquartered, LSE-listed company (ticker HIK) founded in Jordan in 1978, with roughly 9,500 employees and core revenue of about $3.1 billion (2024).

Operations. Roxane develops, manufactures and sells generic prescription pharmaceuticals from an ~875,000 sq. ft. Columbus campus. Capabilities include immediate-release and extended-release oral solids, liquids, nasal sprays and dry-powder inhalers, plus high-potency/oncology compounds and DEA Schedule I–V controlled substances; at acquisition the site made 88 products and carried a pipeline weighted toward Paragraph IV and first-to-file challenges. Customers are wholesalers, retail chain pharmacies and group purchasing organizations.

Litigation posture. This is an operating company, not an NPE. It appears only as a defendant (2 cases, 0 as plaintiff) — consistent with a generics manufacturer defending antitrust claims rather than asserting patents. Neither tracked case is in a patent-friendly venue; the matters are antitrust suits arising from Hatch-Waxman settlement conduct.

Notable cases. Both tracked matters concern Xyrem (sodium oxybate) and Hikma's 2017 patent settlement with Jazz Pharmaceuticals. UFCW Local 1500 Welfare Fund v. Jazz Pharmaceuticals Ireland Ltd. et al. (E.D.N.Y., filed 2020-06-30) and In re Xyrem (Sodium Oxybate) Antitrust Litigation (N.D. Cal. MDL 20-md-02966) alleged reverse-payment and market-allocation conduct delaying generic Xyrem. Hikma agreed to a $50 million settlement in that MDL; Jazz agreed to $145 million ($195 million combined, given final approval November 2025). Plaintiff-side damages estimates were reported around $1.84 billion. Hikma has separately defended generic-drug antitrust claims in the Eastern District of Pennsylvania MDL.

In re Xyrem (Sodium Oxybate) Antitrust Litigation

ongoing; trial set May 19, 2025; settlements with Amneal and Lupin final approval April 17, 2024
Patents:8589182

Consolidated MDL antitrust litigation concerning Xyrem (sodium oxybate). U.S. 8,589,182 is listed among the patents cited/at issue. Class certification and summary-judgment motions have been decided; trial set for May 19, 2025.